Ardelyx’s (ARDX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Ardelyx (NASDAQ:ARDX) in a report released on Friday morning, Benzinga reports. HC Wainwright currently has a $11.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Ardelyx’s Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at $0.01 EPS and FY2026 earnings at $0.58 EPS.

Several other analysts also recently issued reports on the company. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Ardelyx in a report on Friday, August 2nd. StockNews.com upgraded Ardelyx from a “sell” rating to a “hold” rating in a report on Wednesday, July 31st. Finally, Citigroup increased their price objective on shares of Ardelyx from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $11.67.

Ardelyx Stock Up 3.7 %

ARDX opened at $6.09 on Friday. Ardelyx has a 1 year low of $3.43 and a 1 year high of $10.13. The firm has a 50 day moving average price of $6.07 and a 200 day moving average price of $6.32. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.99 and a current ratio of 4.21. The company has a market cap of $1.43 billion, a PE ratio of -20.30 and a beta of 0.92.

Ardelyx (NASDAQ:ARDX) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.04. Ardelyx had a negative net margin of 28.82% and a negative return on equity of 46.86%. The company had revenue of $73.20 million during the quarter, compared to the consensus estimate of $55.03 million. During the same period in the previous year, the firm earned ($0.08) earnings per share. Ardelyx’s revenue for the quarter was up 228.3% on a year-over-year basis. Sell-side analysts expect that Ardelyx will post -0.25 earnings per share for the current year.

Insider Buying and Selling at Ardelyx

In related news, CFO Justin A. Renz sold 5,289 shares of Ardelyx stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $5.86, for a total value of $30,993.54. Following the completion of the sale, the chief financial officer now owns 295,257 shares in the company, valued at approximately $1,730,206.02. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider David P. Rosenbaum sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $5.94, for a total value of $118,800.00. Following the completion of the sale, the insider now directly owns 356,479 shares in the company, valued at approximately $2,117,485.26. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Justin A. Renz sold 5,289 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $5.86, for a total value of $30,993.54. Following the transaction, the chief financial officer now owns 295,257 shares in the company, valued at $1,730,206.02. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 212,126 shares of company stock worth $1,298,963 in the last 90 days. 5.90% of the stock is owned by corporate insiders.

Institutional Trading of Ardelyx

Several institutional investors have recently added to or reduced their stakes in ARDX. Redmile Group LLC acquired a new position in shares of Ardelyx in the 1st quarter valued at about $16,020,000. Millennium Management LLC lifted its holdings in shares of Ardelyx by 142.8% in the 2nd quarter. Millennium Management LLC now owns 3,203,090 shares of the biopharmaceutical company’s stock worth $23,735,000 after purchasing an additional 1,883,995 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Ardelyx by 68.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,913,863 shares of the biopharmaceutical company’s stock worth $28,572,000 after buying an additional 1,584,597 shares during the last quarter. Vanguard Group Inc. increased its position in Ardelyx by 2.8% in the first quarter. Vanguard Group Inc. now owns 13,391,855 shares of the biopharmaceutical company’s stock worth $97,761,000 after buying an additional 365,809 shares during the period. Finally, Squarepoint Ops LLC increased its position in Ardelyx by 375.9% in the second quarter. Squarepoint Ops LLC now owns 460,689 shares of the biopharmaceutical company’s stock worth $3,414,000 after buying an additional 363,894 shares during the period. Institutional investors own 58.92% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.